Prostate Cancer Clinical Trials in Philadelphia

Showing 241-260 of 387 trials

NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma

NCT02805894

This study is a Phase 1/2 open-label involving 2 groups of patients newly diagnosed with either unfavorable intermediate risk or high risk prostate adenocarcinoma. One group will receive only EBRT and the other group will receive a Brachytherapy boost and EBRT. Both groups will receive treatment with androgen deprivation. There will be 2 consecutive steps, a dose escalation and a subsequent dose expansion part.

Prostate Cancer

Nanobiotix5 participantsStarted Nov 2017

Boston, Massachusetts, United States • Philadelphia, Pennsylvania, United States

COMPLETEDPhase 1< 1 mile

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

NCT01338831

The purpose of this first multi-dose study in cancer patients is to determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D), characterize the safety, tolerability and pharmacokinetics profile. Once the MTD has been established and/or a RP2D chosen, the study will enroll patients into the expansion portion of the study.

Castration-resistant Prostate CancerMetastatic Breast CancerUterine Leiomyoma

Novartis Pharmaceuticals73 participantsStarted Sep 2011

Boston, Massachusetts, United States • New Brunswick, New Jersey, United States • Philadelphia, Pennsylvania, United States +6 more locations

NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

Prostate Cancer Trials in Other Cities

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

A Registry for Hereditary Cancer Risk Assessment and Genetic Testing

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

Collecting and Storing Blood and Tumor Tissue Samples From Patients Undergoing Prostatectomy or Transurethral Resection of the Prostate

Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

A Survivorship Care Plan and Embedded Navigation Tool

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Other Conditions in Philadelphia